Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
21.48
+0.36 (1.70%)
Nov 16, 2026, 3:20 PM EST - Market open
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

HDV and Gilead-led HSV-2 phase II data are expected in H2 2027, with PBC/PSC data in H1 2028. ABI-6250’s oral NTCP mechanism spans HDV and cholestatic disease, while opt-in rights and 40/60 economics shape development options.

Ash Verma
Analyst, UBS

Good day, everybody. Welcome to UBS Biopharma Conference in London. I'm really excited to have the Assembly Bio team with me. Jason Okazaki, who's the President and CEO, Katie Kitrinos, and Anuj Gaggar. Guys, thank you so much for joining us. Really excited to know more about what's going on with Assembly Bio.

Maybe it'll be helpful if you can give a little bit of a background about Assembly. You just reported third quarter earnings, initiated a trial, I guess, or your partner Gilead did that. Just help us understand the platform and give some context so that we can dive more into more specific questions after that.

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, absolutely. And thanks for having us, Ash. Pleasure to be here. So yeah, so really the company's evolved over the past six years since really this team has been here from focused solely on hepatitis B cure to broader antivirals and actually liver disease. So what you're referring to is kind of the fruition of the pipeline we've built over the past six years. So with the lead being the HSV-2 high recurrent genital herpes asset.

As you noted, that's now partnered with Gilead. Gilead opted into that program based on some very positive phase I-B data last year. They control that program and just initiated the phase II, which will be head-to-head against Valtrex, which is what we'd expected to do if we were running the program. So looking forward to the progress on that.

Then we have ABI-6250, which is a small molecule oral entry inhibitor that originally we were developing for hepatitis delta, and that study actually initiated just two weeks ago. In May, we actually announced, and we've been looking at this for the past couple years, is really cholestatic liver diseases. So given the functionality of it being an NTCP inhibitor, and we'll talk about this, I'm sure, right? It's got a great mechanistic approach to cholestatic liver diseases, specifically PBC, PSC. So we're looking forward to initiating the phase II trials for those in the first quarter of next year.

This year frames up as a really big execution year, and next year is going to be a very heavy data on year, with the second half of the year we'll have hepatitis D data for ABI-6250, presumably the HSV-2 recurrent genital herpes data from Gilead for phase II, and then starting first half of 2028, we should have the PBC, PSC data. So pretty excited about another big milestone year next year.

Ash Verma
Analyst, UBS

Yeah. Yeah, that's great. Let's talk about that. I mean, I guess the phase II clinical trial design got outlined at this clinicaltrials.gov. If you can talk about it, what are some of the key things to focus on? It looks like two weekly doses that you're comparing in 300 patients. Then, in this type of setting, is there a right level of enrollment pace that would help selecting the right patient population for this study?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. Thanks for asking the question.

Ash Verma
Analyst, UBS

Yeah.

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

The phase II study, as was posted by Gilead on clinicaltrials.gov, gave us some insight as to how they're designing it, which is much in line with how we would design a similar study. As you said, there's three arms. There's a low-dose arm, a high-dose arm, and a valacyclovir control arm, and it's a 12-week dosing period.

What we know about the patient population they've selected, as noted there, is it's similar to the one that we had in our phase I-B studies for both ABI-5366 and ABI-1179. That patient population makes up the majority of the patients that are out there on treatment, and they are, we know from our experience, it enrolled quite rapidly, because it is a pretty open enrollment criteria there.

We do expect, and as posted by Gilead, that they're expecting to have the trial completed by the end of next year. We think that's a reasonable pace for that kind of a study, and I think the outcomes are going to be really exciting to look at. As we would have done in our phase I-B, we went against placebo, and the next step for that molecule is to go against the standard of care, valacyclovir. But as you point out, one of the main advantages is not just better efficacy, but that once-weekly dosing, which is a big improvement on convenience from the daily dosing of valacyclovir.

Ash Verma
Analyst, UBS

Yeah. When we think about the focus on the viral shedding and the tracking the lesions, if you can talk about what type of benefit compared to valacyclovir would be pretty meaningful, either on either of the endpoints.

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. These are two very interesting ways of looking at the impact of the drug. The shedding rate is a more quantitative measure that's a little easier to get data for with a smaller group of patients and power a study for that.

Ash Verma
Analyst, UBS

Yeah.

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

My guess is the powering of that study may be based on the shedding versus valacyclovir. There's good precedent from pritelivir, a previous helicase-primase inhibitor, which went head-to-head against valacyclovir and beat it on shedding. We know that ABI-1179 is more potent than pritelivir, and we predict to have a higher efficacy than pritelivir.

I think from a primary endpoint, probably that shedding is going to be very important, and we expect to see positive signal there. For lesions, the longer you evaluate patients, the more likely you are to pick up lesions and find a statistical difference between two arms. It's not clear right now if the 12 weeks is going to be sufficient and the number is sufficient. We would expect directionality at least in the direction of improved lesions with ABI-1179 versus valacyclovir.

These molecules and the programs themselves were designed to have better efficacy than valacyclovir. We would expect to see certainly statistical significance on, let's say, the shedding endpoint and directionality probably on the lesions as well.

Ash Verma
Analyst, UBS

Got it. Does that change in any way, like in subsequent trials? Does lesion at some point need to become a primary?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. Great question. I think there's no specific guidance from the agency on genital herpes, but from their oral herpes guidelines, you can extrapolate that lesions are probably the most important thing in a phase III study.

Ash Verma
Analyst, UBS

Right.

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

The virology data hasn't really been caught up enough to really make it a good surrogate yet, but I think that's a very interesting question that Gilead, I'm sure, will be having with the agency on how you can speed up approvals.

But in lesions, we feel pretty confident that there's a lot of room left on the table from valacyclovir. Only one-third of patients can make it without a lesion for a year on valacyclovir. A lot of ways to improve upon it that in a longer-term phase III study, we feel pretty confident you'd beat valacyclovir on lesions as well.

Ash Verma
Analyst, UBS

Oh, got it. Can you talk about, is there any additional follow-up that would happen for these patients beyond the Q4 timeline readout, or in terms of the efficacy and any tolerability areas of focus on what are some of the side effects of interest?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, I think the way they've designed the study is appropriate, which is the 12-week dosing period and then a follow-up period, a short follow-up period off drug, just to see-

Ash Verma
Analyst, UBS

Right

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

as we often do in these studies. The key is going to be that dosing period. I think by the time we get to the data by the end of next year, it should include all the efficacy and safety data that helps de-risk it for further development.

Ash Verma
Analyst, UBS

All right. Okay. Some of the things that you're looking out at in terms of the market size of this opportunity, there are [80,000 patients] that are on chronic valacyclovir. When you think that this program comes to the market, would that be really just like taking share from valacyclovir, or can it expand the pie beyond that?

Jason Okazaki
President and CEO, Assembly Biosciences

I think it's a little of both. If you look at it from a market perspective, we've done this analysis two ways. Top-down, which is epidemiology, it's pretty evenly split, 2 million between the U.S. and 2 million in the EU as far as patients. We did a deeper dive, I think is what you're referring to, Ash, is from a bottoms-up analysis looking at ICD-10 codes and then Valtrex scripts for 90 days or more, which is kind of indicative of the chronic suppressive market.

We did that in conjunction with University of Washington, which is probably the globally renowned institution for HSV-2 research. What that extrapolation showed was there's probably about 1.3 million- 1.4 million patients in the U.S. that are suffering from the condition that would be eligible for chronic suppressive treatment.

Out of that, the extrapolation would also show there's about 700,000 - 800,000 on Valtrex, right? As you said, our point on this is really to win on efficacy and convenience. If you think about when Valtrex launched, they launched purely on convenience. They launched in a generic acyclovir market, still managed about $2.5 billion peak. Granted, that was about 10 - 15 years ago, and they had some other indications.

But we're very optimistic as we look at the market of, if you just take that 800,000 patients, right, and we've tested pricing with payers with the TPP at once weekly superiority of Valtrex and gotten the consistent feedback that we could expect a moderate premium to branded Valtrex, which was priced around $5,500 a year. As you can imagine, we tested pricing somewhere between $5,500 and $10,000, let's call it.

Going back to that math analysis, if you just took dumb math and half of that 800,000 patients estimated currently on therapy and converted them to ABI-1179 and priced it par Valtrex, that's a $2 billion + market on its own. Of course, we all know from our experience in virology that the better the drug, the more people are on drug, and the more the market expands to actually people that aren't currently seeking treatment will come to seek treatment. Because as the news noted, even by Valtrex's own label, two out of three patients are having recurrences. This is a very large unmet medical need.

Ash Verma
Analyst, UBS

Right. Yeah. When you think about the payers, what they're looking for in terms of the TPP, is that the efficacy and safety differentiation, is that the bottom line, or does the administration burden becoming lower also make a big difference?

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, I think the convenience is important, but from our standpoint, and I think from the payer standpoint, having the higher efficacy is what's really going to drive both reimbursement and the labeling.

Ash Verma
Analyst, UBS

Yeah. Got it. Okay. All right. Maybe just switching gears to the chronic HDV now. Yeah, you've dosed some patients here, I think, and guiding to data by the end of next year too. Yeah, if you can talk about just like how many patients, just to give a little bit of a background, how many patients, what the pace of enrollment, what type of patients are you looking for particularly?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, so for hepatitis delta, it's a trial we're very excited about. Like you said, we just initiated dosing a couple of weeks ago. Just as a reminder, the approved drug, the only approved drug is bulevirtide by Gilead, which is a peptide inhibitor of NTCP. So we know this target is validated, it's safe, well-tolerated, and has benefits to patients over time in terms of their liver disease.

Our team worked to make a small molecule inhibitor of NTCP that could replace bulevirtide but create the same function of blocking the virus from entering hepatocytes. After the phase I-A data, we have really great pharmacodynamic activity, and so we've taken that now into this phase II study. The phase II design, there's two cohorts. The first cohort is really the one that's meant to help us choose the dose.

We have a low dose versus a high dose versus a delayed treatment arm, and it's 20 patients in the treatment arms and 10 in the delayed treatment arm. After 16 weeks, we'll look at the data, the viral load curves, and be able to choose a dose, and then that dose will go into our expansion cohort.

The expansion cohort is there to provide additional safety data for when we do our submissions for phase III afterwards, that we have enough patients that have been dosed with that particular dose that we take forward. All patients will be followed till 48 weeks of treatment, so we'll have not just that 16-week data, but we'll have longer-term data for safety and efficacy also.

Ash Verma
Analyst, UBS

The 4Q data update next year is going to be the 16-week, and the 48-week is like the subsequently, probably in 2028, some point of time?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, that's correct. I think that's what we're moving towards. Of course, we're trying to roll this as rapidly as possible, and I think we're doing great so far in enrollment.

Ash Verma
Analyst, UBS

Right. You had some phase I-A data at AASLD. Just help us understand, how does that build your confidence in terms of selecting the right dose and the NTCP mechanism?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, so there's a few aspects that were useful from that phase I-A study, and we presented some of the more detailed data at AASLD, at The Liver Meeting. One's, of course, safety, and we have to make sure that we have a pretty safe molecule, and I think that that was pretty well borne out by the poster that we showed, that tolerability looks pretty good.

Sometimes people worry about creating itch with elevated bile acids. We didn't see any of that in the studies as well. Pharmacokinetics are important, and we want to make sure we get to a once-daily dosing, and we have a four-day half-life with the molecule, so it's pretty easy to get to once-daily dosing. The last is the pharmacodynamics, so how well are we hitting the same receptor that bulevirtide is hitting?

One nice part about hitting this receptor is that you elevate bile acids as a pharmacodynamic measure in the periphery, so we can compare then how we elevate bile acids to how bulevirtide elevates bile acids. With the doses that we think we want to move forward with, we can certainly match and potentially exceed the bile acid elevation that bulevirtide saw.

What we showed at AASLD was some of the more detailed bile acid analysis showing conjugated bile acids being blocked primarily by our ABI-6250, which is expected given its target is NTCP. Just more mechanistic data that says that we are actually hitting the target that we intended and not hitting any other targets that we're not intending.

Ash Verma
Analyst, UBS

All right. Okay. When you think about the way this is working, is it possible that the antiviral benefit levels off while the bile acid keeps rising? Could that help in identifying effectively the most optimal dose that can achieve both these criteria?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

So short answer is yes, that we have used that data to choose the doses for our phase II program. There is a probably maximum inhibition, like with any virus, that you can do with these kind of mechanisms, and bile acids have many other ways in which they can increase.

I think the short answer is yeah, we've used that data already, and the doses that we've selected for our phase II are ones that took into account the bile acid elevation, took into account how that relates to virology based on bulevirtide, to eventually get to the doses that we're taking to phase II.

Ash Verma
Analyst, UBS

Great. Okay. When you think about the expansion cohort, yeah, I guess people who might not be familiar with this space a little bit, just if you can talk about what's the rationale for including that, what does that tell you, and what would be ultimately the bar for success in that type of a setting?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, so for this is orphan disease in the EU and most likely in the U.S. to be considered that at some point soon. We know that having the right safety database at phase II is critical for moving into phase III. If you look at other folks in this space, they've generally hit around the same number of patients dosed to get into phase III. So our goal is to take this phase II study and enable a phase III right afterwards. That cohort is confirmation of efficacy, it's confirmation of safety, and it's creating that database that then when we go to the agencies, we have enough safety to allow a phase III to occur.

Ash Verma
Analyst, UBS

Yeah. Okay. How should we think about the combined measure of viral response and ALT normalization?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah, it's a really important part of delta development right now is that the agencies have asked for a composite endpoint. They want to make sure you, one, have an impact on the virus, so there's a virologic component, which is two-log decline or becoming undetectable. The second piece is a functional benefit on the liver, which is an ALT normalization, and you have to meet both of those to have an impact.

We look at the agents that are out there right now, so the approved agent from Gilead, bulevirtide, and the ones in development that are in phase III from Mirum and from Vir, and together, they all are acting to prevent new hepatocytes from being infected. So they're all acting as functional entry inhibitors.

Some, like ABI-6250 and bulevirtide, block a virus from entering at the receptor level, and some, like the antibody-based mechanisms, block the virus from entering by on the virus level. What we see is that that data, and there was some phase III data released at AASLD, shows that the composite endpoint for those newer modalities are similar to what bulevirtide showed, which is what we expect.

So that roughly 50% range of hitting the composite endpoint is what we're seeing from the competitors, and we expect to also get something similar to that, again, with being an oral small molecule versus all the injectables that are out there right now.

Ash Verma
Analyst, UBS

Right.

Jason Okazaki
President and CEO, Assembly Biosciences

But we think as far as the importance, I would say ALT is the most important measure from a patient standpoint. I think that's what we're monitoring most closely. So, to the extent we can match bulevirtide being a small molecule oral, that's really the goal, is ultimate simplicity, but the same efficacy that, like Anuj says, really been seen across the field.

Ash Verma
Analyst, UBS

Great. Okay. Here, maybe if you can give a little bit more background on just what is the patient size market in terms of market opportunity and what type of-

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, like Anuj says, it is an orphan market, right? So it is a small profile that varies drastically as far as who you talk to. I think the estimates are somewhere between 40,000 and 150,000 in the U.S. Out of that, again, bulevirtide just launched. We will see how that uptake goes.

It is a more complex regimen for sure, but the efficacy is great, so that will be a great first mover for us. I think actually in this situation, us being toward the end or the last entrant will be to our advantage as companies still build up the market in the U.S. But as Anuj noted, all those other therapies, whether it be bulevirtide, Mirum, Vir, they are all injectables or antibodies.

Ash Verma
Analyst, UBS

Yeah

Jason Okazaki
President and CEO, Assembly Biosciences

Convenience, certainly, it is getting more convenient with each generation, which I think is a positive for patients, and ultimately, we will be the only small molecule oral, which all these patients are on hepatitis B therapy, oral nukes essentially. Whether or not they are taking two pills a day or even co-formulating, I think our experience from a patient standpoint is that is going to be a lot more effective from a therapeutic standpoint and give a lot more optionality.

Ash Verma
Analyst, UBS

Is the corridors around the pricing in this segment pretty set, or is there some wiggle room?

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, I mean, again, it's new, right? The bulevirtide WAC was $285,000, I believe. Again, consistent with an orphan market. We would have an advantage as a small molecule for simplicity and pricing, but I think it's a ways out. But again, it's probably going to be an orphan market, so higher price, but with smaller patient population.

Ash Verma
Analyst, UBS

Got it. Okay. When you get to the market for this, I know this is kind of like data generation mode right now, but do you think that the adoption for your molecule would be more from the established injectable treatment options switching over, or could it be more naive patients coming into the mix?

Jason Okazaki
President and CEO, Assembly Biosciences

I think hopefully both, right? Because kind of talking about our HSV-2 discussion, as each generation of compound and drug is better, hopefully it's encouraging more diagnosis, more treatment, so that 50,000 patient becomes maybe 200,000 or 250,000, in which case-

Ash Verma
Analyst, UBS

Yeah

Jason Okazaki
President and CEO, Assembly Biosciences

You hopefully, next four or five years as we progress, not only more patients getting treated, the market's getting bigger. Whether or not you're taking naive or from existing therapies, doesn't matter to us, or if Gilead or opts in, I'm sure it wouldn't matter to them either, but as long as people are getting treated with the best therapies at the time, and we would hope that ours is ultimately the best and the simplest.

Ash Verma
Analyst, UBS

Got it. Okay. Maybe just like moving over to PBC and PSC, just like where do you think mechanistically, why could blocking NTCP actually be effective in these indications?

Katie Kitrinos
SVP of Preclinical Research and Development, Assembly Biosciences

Yeah. As both Jason and Anuj said, our initial target with developing ABI-6250 was for delta, and NTCP is the entry receptor for delta and HBV. However, the primary function of NTCP is bile acid transport. We know that cholestatic liver diseases like PBC and PSC are driven by elevations in intrahepatic bile acids that result in progressive damage to the liver.

When we were initially studying ABI-6250, in addition to having low nanomolar potency against delta, we had low nanomolar potency against bile acid transport. So we think that it will be effective in the cholestatic liver disease population. I'd say additionally, we know that the majority of bile acids in the body, 75%-95%, are recycled.

So we think there's the potential with ABI-6250 that it could actually have a greater reduction in intrahepatic bile acids relative to the PPARs, which are blocking de novo production of bile acids. But we'll be evaluating that in the phase II study.

Ash Verma
Analyst, UBS

Great. What are the next steps here, just in terms of initiating the phase II combined PBC/PSC study in 1Q, just to help us understand, like how do you intend to operationalize that?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. We had a meeting with the agency, a pre-IND meeting in May, where we discussed our plan to do a basket study, which is for us a very efficient way to ask several questions in the same study. That study right now, as you mentioned, is being stood up to be launched at the beginning of next year. In that study, we're looking at PBC and PSC, and in PBC, we're looking at two different cohorts. One is a second-line therapy, which is patients who have failed or intolerant or have an inadequate response to UDCA, and then we add our drug on top of that. The second cohort is a third-line therapy.

These are patients who, same thing with UDCA, but then they're also on a PPAR and have had an inadequate response to PPAR, and then we add on our therapy to that as well. We'll understand quite a bit about what happens with our drug with a PPAR and UDCA or with UDCA alone. In PSC, there's no approved agents, and so we would expect some will be on UDCA, but it'll be first-line therapy in PSC.

Ash Verma
Analyst, UBS

Got it. Any sense on, yeah, what's either the endpoint, size of the trial, things of that nature?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. For PBC, it's pretty well established that alkaline phosphatase reduction is the grounds for an accelerated approval. It's a validated surrogate for PBC. Of course, we'll be measuring alkaline phosphatase reduction as the primary endpoint of that portion of the study.

In addition, we're looking at other markers of fibrosis and non-invasive markers of fibrosis, as well as, because PBC patients also suffer from a lot of impacts on their daily lives from fatigue and from itch. We'll be measuring those by specific scales and PROs. That will tell us what the path of approval can be. In PBC, you can get things approved on itch alone or on disease modification with alkaline phosphatase, or both. I think we'd like to see what the impact is there. In PSC, it's a little more complicated.

There's no validated surrogate endpoint for disease progression right now, so you cannot use alkaline phosphatase, though that seems like still an important measure. We will look at alkaline phosphatase as well as fibrosis changes with non-invasive measures and all these other PROs as well. That's one area where itch reduction can be an approvable endpoint, so we'll understand the impact of this mechanism on itch in that cohort. At the end of this, we'll have an evaluation for all three cohorts on multiple domains, and I think from that, we'll be able to launch the most efficient phase III program after that.

Ash Verma
Analyst, UBS

Oh, and they would bifurcate that they would be separate phase III clinical trials for PBC and PSC, right?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

I think for cholestatic pruritus, you could do a combined study. The agency-

Ash Verma
Analyst, UBS

Yeah

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

seems to favor that. But if you're going for disease modification, they end up being separate. We'll see what the endpoints that are making the most impact are, and then we'll design that after.

Ash Verma
Analyst, UBS

Okay. Any thoughts on dosing here? I think you've said that you'll test three doses initial stages and then choose two out of it. What's driving that? What type of metrics are you looking for choosing these doses?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. In general, in the history of cholestatic diseases and people taking different medicines there, often those are more sensitive patients than a non-cholestatic patient. Sometimes you need to dose a little bit lower in cholestatic patients than in other indications. Because of that, we wanted to run the sentinel cohorts for both PBC and PSC before we commit to the full cohort.

Those sentinel cohorts will establish from three different doses, which are the most efficacious and safe doses to move forward. Safety is the real thing to look for in that first 28 days from the sentinel cohort. We'll do that with 15 total patients in PBC and 15 total patients in PSC. From there, choose the two doses to then go into the expansion cohorts. I think that's when we expect to see the full data set from, in terms of powering for endpoints.

Ash Verma
Analyst, UBS

Yeah. Is there anything that you would learn from the HDV development, from a safety standpoint that can help sort of guide what type of doses are most optimal for PBC, PSC?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

I think in general, it is nice to see some more safety data with your molecule at different doses in patients. However, the cholestatic group, there is a certain safety that is different for those patients that has to be really done in those patients alone. I think while we will learn some data from it, I think the bulk of it is going to come from that trial itself in cholestatic patients.

Ash Verma
Analyst, UBS

Yeah. Okay. For the patients that are in second or third-line PBC groups, yeah, would the efficacy metrics look different based on what they had already been on, like the exposure that they have had to different therapies in the past?

Anuj Gaggar
Chief Medical Officer, Assembly Biosciences

Yeah. This is a really exciting scientific area of bile acid metabolism where we are going to learn a lot. I think the field is going to learn a lot through these studies too. Also, the field is moving from one point. It used to be that, well, right now it is 1.67 x the upper limit of normal of alkaline phosphatase is the goal of therapy.

But the field and a lot of KOLs really want to normalize alkaline phosphatase because they feel like we should not allow for abnormal levels of an enzyme that we think is causing problems in the liver. When you look at the PPARs, they do a really good job of bringing people below 1.67 ULN, but the majority of patients do not go below upper limit of normals. They do not normalize.

For us, there is a lot of room there where you could add another mechanism and bring all those patients down to a normal alkaline phosphatase. There is also reason to believe that, as Katie pointed out, that the majority of bile acids are entering through NTCP. We may actually have a better impact than a PPAR does. One could see this moving into second-line therapy if we see a better impact in our trial. The fact that our trial is establishing a second-line data set and a third-line data set sets it up again for not where the field is now only, but also where it might be going into the future.

Ash Verma
Analyst, UBS

Got it. Okay. Then, just in terms of maybe Jason, coming back to the whole discussion around the partnership. I mean, you have a lot of different optionalities here. Are there some indication that you are still pursuing that are not partnered? Would you be open to partnership discussion with Gilead or any other companies for that matter?

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, Gilead has opt-ins to all of our programs.

Ash Verma
Analyst, UBS

Right.

Jason Okazaki
President and CEO, Assembly Biosciences

Of course, as any of these collaborations works, you know, they are not going to opt in to everything, right?

Ash Verma
Analyst, UBS

Yeah.

Jason Okazaki
President and CEO, Assembly Biosciences

I think certainly, obviously HSV-2 made a lot of sense, large market potential. As they noted, or we noted as well, they are actually looking at that for a dual PrEP as well for HIV and HSV, which would be incredibly intriguing and great from a patient perspective. You know, delta, they have an opt-in as well, ABI-6250, and they are active in those spaces. Obviously, it is their decision. But if they do not opt in, at that point, we decide whether or not to take things ourselves or to re-partner them.

Then starting after actually ABI-7272, which is our newest molecule that we will be entering clinic next year, we have the 40/60 cost profit share on all the current assets. But with the new molecules, we have a co-promote option as well. So that allows us to kind of build an end-to-end business. I think the way the partnership is really structured allows us to kind of grow as an end-to-end biotech down the road.

Ash Verma
Analyst, UBS

Yeah. But these type of, like having the opt-in, do you think for Gilead, would the clinical trial data be the trigger of making the next decision?

Jason Okazaki
President and CEO, Assembly Biosciences

I think certainly for ABI-6250, I think once that delta data comes out, that will really inform their decision. And their opt-in point would be at the end of phase II, and then they have to decide to opt in or opt out at that point.

Ash Verma
Analyst, UBS

Yeah. But it could be that, like just going after delta and not necessarily PBC, PSC, which you might want to retain. Is that a possibility?

Jason Okazaki
President and CEO, Assembly Biosciences

They could. It's an option per program. They would take the opt-in for ABI-6250, and they would decide what to do with it. Of course, given their business platform, you would think it would, you know, if the data worked for both ways, it would certainly fit into what they're doing right now.

Ash Verma
Analyst, UBS

Right. Okay. Perfect. This is great. Yeah. Thank you so much. Maybe just wrapping up, if you can outline some of the catalysts for investors, and we can wrap.

Jason Okazaki
President and CEO, Assembly Biosciences

Yeah, no, absolutely. I kind of alluded to it earlier, but, you know, really starting second half of next year, you're going to have the delta data. You know, we'll have hopefully HSV-2 data, you know, from Gilead. Then, you know, first half of 2028, you're going to have PBC, PSC.

So those are three incredibly large catalysts, which right now we're well funded into 2029, so we have that cushion about a year beyond 2028. But of course, if any of those or all those hopefully pan out, then we're funding for phase III and commercialization, either through our 40/60 profit share or on our own, depending on the results of the opt-in.

Ash Verma
Analyst, UBS

Great. This is awesome. Thank you so much.